CDK4 and breast carcinoma: The MONARCH 3, MONALEESA-2 and PALOMA-2 studies represent pivotal phase 3 studies establishing the role of CDK4/6 inhibitors in the first-line treatment of HR+/HER2− advanced breast cancer [6,7,8].